Pyxis Oncology, Inc. PYXS 深 滬
已收盤 06-18 16:00:00 美东时间
2.03
+0.130
+6.84%
華盛通- 最 高2.07
- 今 開1.90
- 成交量 66.87万股
- 最 低 1.90
- 昨 收 1.90
- 總市值 1.29亿
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 1.06%
- 52周最低 0.97
- 委 比 -35.42%
- 總股本 6335.55万
- 歷史最高 19.00
- 量 比 1.25
- 振 幅 8.95%
- 歷史最低 0.8332
- 每 手 1
- 風險率 1.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pyxis Oncology shares are trading lower. The company reported Q1 financial results.
Pyxis Oncology shares are trading lower. The company reported Q1 financial resu...
05-15 03:49
Pyxis Oncology Q1 EPS $(0.37), Inline
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 5.71 percent decrease over losses of $(0.35) per share from the same period last year.
05-14 19:16
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6
Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperform rating and announces Price Target of $6.
05-05 21:26
Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNSCC Model With maMICVO In Combination With Anti-PD-1 at AACR 2026
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will present new preclinical data highlighting that a mouse
04-18 04:07
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
03-24 19:06
Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.33) by 12.65 percent. This is a 50.85 percent increase over losses of $(0.59) per share from
03-23 19:12
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
2025-12-19 22:07
